After more than two years of investigation, the Democratic-led House Select Subcommittee on the Coronavirus Crisis released its final report Friday, shining a harsh light on the federal government’s response to Covid-19.
The committee, chaired by Rep. James Clyburn (D-SC), accuses the Trump White House of “failed stewardship over the pandemic response,” saying the administration showed a “persistent pattern of political interference” that undermined the nation’s public health capabilities. "The Trump Administration’s reckless pandemic response resulted in devastating and lasting harm," the report says.
Among other problems, the Trump administration failed to change its approach to the crisis as expert understanding of the virus improved. It also failed to coordinate the efforts of health officials, reducing the effectiveness of the federal response.
The 218-page report blames former president Donald Trump personally for the politicization of the federal Covid response, which it says contributed to the spread of misinformation that ultimately cost thousands of lives:
"Much of the phenomenon of coronavirus misinformation can be traced to President Trump and his efforts to politicize the pandemic. In addition to treating the coronavirus crisis as a political problem, the former President pushed lies about risks posed by the virus and took steps to undermine the scientists who were working to address America’s worst public health crisis in a century. …
"The former President’s spread of falsehoods became even more insidious as the pandemic continued. … The former President repeatedly advocated for the use of hydroxychloroquine to treat the coronavirus and claimed at one point that a study finding hydroxychloroquine ineffective as a coronavirus treatment was authored by 'people that aren’t big Trump fans.' He frequently attacked those who were willing to contradict his lies …
“Research has … found direct causal links between the former President’s lies about the pandemic and the spread of misinformation. A study at Cornell University analyzed 38 million articles about the pandemic in English-language media around the world and concluded that President Trump was the single largest driver of coronavirus misinformation between January 1 and May 26, 2020. The researchers found that President Trump’s promotion of ‘miracle cures’ like hydroxychloroquine significantly contributed to the spread of misinformation. By feeding the public falsehoods about the coronavirus and coronavirus treatments, the former President made it more difficult for Americans to distinguish between legitimate and illegitimate sources of health information. This also made it harder for Americans to know how to protect themselves and their loved ones from the coronavirus, ultimately threatening the health of the American people.”
The report also faults the Trump administration’s economic relief efforts during the pandemic. “Poor implementation and oversight of federal aid programs, combined with unscrupulous private actors, led to significant waste, fraud, and abuse and a less effective pandemic response,” the report says.
Republicans reject the report’s findings: Steve Scalise (R-LA), the ranking member on the committee, said the report was purely political, citing conservative theories that fell outside the analysis. “Democrats refused to investigate after we exposed the Biden White House manipulating the science to allow a radical teachers union to rewrite CDC guidance so they could make it easier to shut down schools,” Scalise said. “They refused to investigate the origins of COVID-19 and efforts by Dr. [Anthony] Fauci to downplay the Wuhan lab leak theory.”
Senate report also faults Trump response, public health system: In a separate report released Thursday, the Senate Committee on Homeland Security & Governmental Affairs provided its own analysis of the crisis, which also finds extensive fault with the Trump administration’s response, as well as with the nation’s public health system more broadly.
Among its many findings, the 242-page report says the U.S. failed for years to invest sufficiently in public health infrastructure, resulting in “inadequate, antiquated, and fragmented” surveillance and production systems. Once the crisis arrived, government communications were “inconsistent and sometimes contradictory,” delaying a coherent response.
"The suffering that was caused by the pandemic" was "not inevitable," committee chair Gary Peters (D-MI) said. "We could have handled this situation a whole lot differently."
What comes next? Both reports provide extensive recommendations for how to improve the federal government’s preparation for and response to the next crisis. Those recommendations include increasing investment in public health infrastructure such as testing and surveillance; better defining lines of authority and communication within the federal government; and boosting domestic productive capacities for essential medical equipment.
“The coronavirus crisis will not be the last public health emergency or economic crisis that we confront,” Clyburn warned.
Like what you're reading? Sign up for our free newsletter.
The number of illegal firearms seized by UK Border Force is set to reach its lowest level in a decade despite concerns over gun crime.
Harpoon Therapeutics Inc (NASDAQ: HARP) presented updated interim data from its Phase 1 trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma (RRMM) at the American Society of Hematology (ASH) Annual Meeting and Exposition. As of the data cut-off date of October 17, the interim results showed that HPN217 demonstrated clinical activity and a tolerable safety profile in heavily pre-treated patients with RRMM (62 patients treated across fixed dose and step dose regimens). HPN
You don't have to be in a hurry when it comes to buying stocks. Here are three top stocks to buy hand over fist before the end of 2022 (listed in alphabetical order). Eli Lilly (NYSE: LLY) should have plenty of good news on the way next year.
France's electricity network operator requested emergency help from Britain as the cold snap caused demand to surge across Europe.
Depending on your age, if your income is below a certain threshold, you may not have to pay taxes. Here's what you need to know.
Aptevo Therapeutics Inc (NASDAQ: APVO) announced that APVO436, in combination with venetoclax and azacitidine, achieved a 100% clinical benefit rate in venetoclax treatment naïve Acute Myeloid Leukemia (AML) patients. The data also showed that APVO436, when given in combination with this standard-of-care regimen, was observed to be generally safe and well tolerated. Clinical activity was observed in both monotherapy and combination cohorts. CRS was observed in fewer than one-quarter of patients
DC brinkmanship is jeopardizing long delayed retirement reform legislation.
The billionaire entrepreneur fears that the economic downturn will become worse if this decision is made.
It seems even 85% of the vote wasn't enough to convince the GOP in another version of election denial.
The U.S. biotech company’s deal for the drugmaker, which develops medicines to treat autoimmune and inflammatory diseases, is the year’s largest healthcare merger.
(Bloomberg) — US household expectations for inflation in the year ahead fell last month to the lowest level since August 2021, according to a Federal Reserve Bank of New York survey.Most Read from BloombergChina’s Rapid Covid Reversal Sparks Whiplash as Cases SurgeUS Says Scientists Make Breakthrough in Nuclear Fusion EnergyFed’s Message That Rates Will Stay on Hold for ‘Some Time’ Clashes With 2023 Rate-Cut BetsElon Musk Steps Up Attacks on Twitter’s Former Safety HeadChina’s Top Medical Advis
Americans are expecting lower increases in inflation in the short term and longer run, according to a New York Fed survey released Monday.
(Bloomberg) — Federal Reserve Chair Jerome Powell has history on his side as he and colleagues split with Wall Street over how long interest rates will stay high in 2023.Most Read from BloombergChina’s Rapid Covid Reversal Sparks Whiplash as Cases SurgeFed’s Message That Rates Will Stay on Hold for ‘Some Time’ Clashes With 2023 Rate-Cut BetsElon Musk Steps Up Attacks on Twitter’s Former Safety HeadChina’s Top Medical Adviser Says Omicron’s Risks Same as FluRussia Is Feeling the Pain of Europe’s
Gilead (GILD) announces deals with Arcellx, Inc. and ImmunoGen to strengthen its oncology pipeline.
The U.S. Supreme Court on Monday agreed to hear President Joe Biden's appeal of a judge's ruling that found his plan to cancel billions of dollars in student debt unlawful, taking up the matter alongside another challenge to the policy that the justices are due to hear in the coming months. The justices will consider the Biden administration's appeal of Texas-based U.S. District Judge Mark Pittman's decision in a challenge backed by a conservative advocacy group, the second of two rulings by lower courts that have put Biden's debt relief policy on ice. The Supreme Court on Dec. 1 said it would hear arguments on the legality of the debt relief program in the other case pursued by six mostly Republican-led states.
(Bloomberg) — Japan and the Netherlands have agreed in principle to join the US in tightening controls over the export of advanced chipmaking machinery to China, according to people familiar with the matter, a potentially debilitating blow to Beijing’s technology ambitions.Most Read from BloombergChina’s Rapid Covid Reversal Sparks Whiplash as Cases SurgeUS Says Scientists Make Breakthrough in Nuclear Fusion EnergyFed’s Message That Rates Will Stay on Hold for ‘Some Time’ Clashes With 2023 Rate
Today, BioSteel Sports Nutrition Inc. ("BioSteel") and global fitness franchisor F45 Training Holdings Inc (NYSE: FXLV) ("F45") announced a new partnership naming BioSteel the exclusive hydration partner for F45 fitness studios globally. Through the partnership, BioSteel will introduce its Clean. Healthy. Hydration.™ products to F45 members directly in-studio, where a zero-sugar hydration routine can help get the most out of a workout.
(Bloomberg) — Last year, officials overseeing New Jersey’s employee health plan — which covers the state’s teachers, cops and other public workers — discovered something that made no sense. The state had been billed $674,856 for a patient’s care at NewYork-Presbyterian. But it had paid $2,026,524, some three times what it was charged.Most Read from BloombergChina’s Rapid Covid Reversal Sparks Whiplash as Cases SurgeUS Says Scientists Make Breakthrough in Nuclear Fusion EnergyFed’s Message That
Sales of Horizon’s thyroid eye-disease drug Tepezza have plateaued, a challenge its new owner will need to contend with.
It's open-enrollment season: Here's what to know if you’re considering a high-deductible health plan.